Psychomotor Agitation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major psychomotor agitation markets are expected to exhibit a CAGR of 1.92% during 2024-2034.
The psychomotor agitation market has been comprehensively analyzed in IMARC's new report titled "Psychomotor Agitation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Psychomotor agitation refers to a set of symptoms characterized by excessive, purposeless physical activity, often accompanied by feelings of restlessness, tension, and irritability. It is commonly associated with numerous psychiatric and medical ailments and can be a manifestation of underlying psychological distress or neurological disturbances. This condition causes an increase in both mental and physical activity, leading to various behaviors, such as pacing, hand wringing, fidgeting, tapping, constantly shifting positions, etc. The agitation can manifest as rapid, purposeless movements and an inability to sit still or relax. It may also include verbal or non-verbal expressions of anxiety, like increased talking or repetitive motions. The diagnosis of psychomotor agitation is typically based on the patient's physical examination, clinical evaluation, laboratory findings, and medical history assessment. Numerous imaging studies, like magnetic resonance imaging (MRI) and computed tomography (CT) scans, may be performed to identify any structural abnormalities or brain-related problems. The healthcare provider may further use the criteria for mental health disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to determine illnesses contributing to the underlying indications.
The rising cases of psychiatric conditions, including bipolar disorder and schizophrenia, that can lead to heightened arousal and a constant state of vigilance are primarily driving the psychomotor agitation market. Besides this, the increasing prevalence of withdrawal symptoms due to abruptly stopping or reducing the use of certain substances, such as alcohol, sedatives, benzodiazepines, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of dialectical behavior therapy, owing to its various advantages, like managing intense emotions, minimizing the frequency of agitation, promoting a sense of relaxation, etc., is further bolstering the market growth. Apart from this, the inflating application of mood stabilizers, which contain valproate or carbamazepine to prevent the worsening of symptoms and enhance the quality of life in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of sensory integration therapy, since it involves activities that stimulate or soothe the senses, such as deep pressure touch or sensory-rich environments, to boost emotional and behavioral control, is expected to drive the psychomotor agitation market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the psychomotor agitation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for psychomotor agitation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the psychomotor agitation market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the psychomotor agitation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the psychomotor agitation market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current psychomotor agitation marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the psychomotor agitation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the psychomotor agitation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the psychomotor agitation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of psychomotor agitation across the seven major markets?
What is the number of prevalent cases (2018-2034) of psychomotor agitation by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of psychomotor agitation by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with psychomotor agitation across the seven major markets?
What is the size of the psychomotor agitation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of psychomotor agitation?
What will be the growth rate of patients across the seven major markets?
Psychomotor Agitation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for psychomotor agitation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the psychomotor agitation market?
What are the key regulatory events related to the psychomotor agitation market?
What is the structure of clinical trial landscape by status related to the psychomotor agitation market?
What is the structure of clinical trial landscape by phase related to the psychomotor agitation market?
What is the structure of clinical trial landscape by route of administration related to the psychomotor agitation market?
The psychomotor agitation market has been comprehensively analyzed in IMARC's new report titled "Psychomotor Agitation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Psychomotor agitation refers to a set of symptoms characterized by excessive, purposeless physical activity, often accompanied by feelings of restlessness, tension, and irritability. It is commonly associated with numerous psychiatric and medical ailments and can be a manifestation of underlying psychological distress or neurological disturbances. This condition causes an increase in both mental and physical activity, leading to various behaviors, such as pacing, hand wringing, fidgeting, tapping, constantly shifting positions, etc. The agitation can manifest as rapid, purposeless movements and an inability to sit still or relax. It may also include verbal or non-verbal expressions of anxiety, like increased talking or repetitive motions. The diagnosis of psychomotor agitation is typically based on the patient's physical examination, clinical evaluation, laboratory findings, and medical history assessment. Numerous imaging studies, like magnetic resonance imaging (MRI) and computed tomography (CT) scans, may be performed to identify any structural abnormalities or brain-related problems. The healthcare provider may further use the criteria for mental health disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to determine illnesses contributing to the underlying indications.
The rising cases of psychiatric conditions, including bipolar disorder and schizophrenia, that can lead to heightened arousal and a constant state of vigilance are primarily driving the psychomotor agitation market. Besides this, the increasing prevalence of withdrawal symptoms due to abruptly stopping or reducing the use of certain substances, such as alcohol, sedatives, benzodiazepines, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of dialectical behavior therapy, owing to its various advantages, like managing intense emotions, minimizing the frequency of agitation, promoting a sense of relaxation, etc., is further bolstering the market growth. Apart from this, the inflating application of mood stabilizers, which contain valproate or carbamazepine to prevent the worsening of symptoms and enhance the quality of life in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of sensory integration therapy, since it involves activities that stimulate or soothe the senses, such as deep pressure touch or sensory-rich environments, to boost emotional and behavioral control, is expected to drive the psychomotor agitation market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the psychomotor agitation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for psychomotor agitation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the psychomotor agitation market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the psychomotor agitation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the psychomotor agitation market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current psychomotor agitation marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the psychomotor agitation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the psychomotor agitation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the psychomotor agitation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of psychomotor agitation across the seven major markets?
What is the number of prevalent cases (2018-2034) of psychomotor agitation by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of psychomotor agitation by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with psychomotor agitation across the seven major markets?
What is the size of the psychomotor agitation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of psychomotor agitation?
What will be the growth rate of patients across the seven major markets?
Psychomotor Agitation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for psychomotor agitation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the psychomotor agitation market?
What are the key regulatory events related to the psychomotor agitation market?
What is the structure of clinical trial landscape by status related to the psychomotor agitation market?
What is the structure of clinical trial landscape by phase related to the psychomotor agitation market?
What is the structure of clinical trial landscape by route of administration related to the psychomotor agitation market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PSYCHOMOTOR AGITATION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PSYCHOMOTOR AGITATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PSYCHOMOTOR AGITATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PSYCHOMOTOR AGITATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PSYCHOMOTOR AGITATION - UNMET NEEDS
10 PSYCHOMOTOR AGITATION - KEY ENDPOINTS OF TREATMENT
11 PSYCHOMOTOR AGITATION - MARKETED PRODUCTS
11.1 List of Psychomotor Agitation Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PSYCHOMOTOR AGITATION - PIPELINE DRUGS
12.1 List of Psychomotor Agitation Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. PSYCHOMOTOR AGITATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PSYCHOMOTOR AGITATION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PSYCHOMOTOR AGITATION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Psychomotor Agitation - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Psychomotor Agitation - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Psychomotor Agitation - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Psychomotor Agitation - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Psychomotor Agitation - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Psychomotor Agitation - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Psychomotor Agitation - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Psychomotor Agitation - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Psychomotor Agitation - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Psychomotor Agitation - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Psychomotor Agitation - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Psychomotor Agitation - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Psychomotor Agitation - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Psychomotor Agitation - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Psychomotor Agitation - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Psychomotor Agitation - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Psychomotor Agitation - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Psychomotor Agitation - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Psychomotor Agitation - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Psychomotor Agitation - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Psychomotor Agitation - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Psychomotor Agitation - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Psychomotor Agitation - Access and Reimbursement Overview
16 PSYCHOMOTOR AGITATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PSYCHOMOTOR AGITATION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PSYCHOMOTOR AGITATION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PSYCHOMOTOR AGITATION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PSYCHOMOTOR AGITATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PSYCHOMOTOR AGITATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PSYCHOMOTOR AGITATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PSYCHOMOTOR AGITATION - UNMET NEEDS
10 PSYCHOMOTOR AGITATION - KEY ENDPOINTS OF TREATMENT
11 PSYCHOMOTOR AGITATION - MARKETED PRODUCTS
11.1 List of Psychomotor Agitation Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PSYCHOMOTOR AGITATION - PIPELINE DRUGS
12.1 List of Psychomotor Agitation Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. PSYCHOMOTOR AGITATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PSYCHOMOTOR AGITATION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PSYCHOMOTOR AGITATION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Psychomotor Agitation - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Psychomotor Agitation - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Psychomotor Agitation - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Psychomotor Agitation - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Psychomotor Agitation - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Psychomotor Agitation - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Psychomotor Agitation - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Psychomotor Agitation - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Psychomotor Agitation - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Psychomotor Agitation - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Psychomotor Agitation - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Psychomotor Agitation - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Psychomotor Agitation - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Psychomotor Agitation - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Psychomotor Agitation - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Psychomotor Agitation - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Psychomotor Agitation - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Psychomotor Agitation - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Psychomotor Agitation - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Psychomotor Agitation - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Psychomotor Agitation - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Psychomotor Agitation - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Psychomotor Agitation - Access and Reimbursement Overview
16 PSYCHOMOTOR AGITATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PSYCHOMOTOR AGITATION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PSYCHOMOTOR AGITATION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
